Moderna, Inc. Common Stock
MRNA · Biotechnology · $61.5B
Powering up
Not on a screen at the moment — no base, so no pivot to draw. The price and volume are below.
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
The read
Moderna, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 99, and it sits in Biotechnology.
Peers
Catalyst roadmap
Nothing dated in the next three months that we can ingest automatically.
Flagged by the market sweep
GappedTape · 2026-09-18
+8.5%
GappedTape · 2026-09-12
+5.4%
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.
In the news
Zacks Investment Ideas feature highlights: NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & SilverZacks Investment Research · 2 days agoIs Cancer the Turnaround Moderna Has Been Looking for Post-COVID?Zacks Investment Research · 4 days agoModerna (MRNA) Ascends While Market Falls: Some Facts to NoteZacks Investment Research · 5 days agoWhy Is Techne (TECH) Down 0.1% Since Last Earnings Report?Zacks Investment Research · 8 days agoMerck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?Zacks Investment Research · 11 days agoBioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?The Motley Fool · 2026-09-03
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray